FeaturedMedia Release
Agreement signals new market opportunities for Race
Race Oncology has announced it has executed a global distribution agreement with UK-based, Durbin PLC.
- Posted by: Race Oncology
FeaturedMedia Release
Race appoints former Sanofi executive to the Board
Race Oncology is pleased to announce the appointment of US-based Dr John Cullity as a non-executive director for Race Oncology.
- Posted by: Race Oncology
FeaturedMedia Release
Viralytics sale signals positive outlook for Race
In a major development for the Australian biotech sector, ASX-listed oncology drug developer, Viralytics, has been sold to US-based big pharma, Merck, for US$502 million.
- Posted by: Race Oncology
Media Release
Second Bisantrene Patent allowed in US
Race Oncology's second Bisantrene patent has received “Notice of Allowance” in the US.
- Posted by: Race Oncology
FeaturedMedia Release
Race Oncology releases Investor Presentation
Race Oncology has released its Investor Presentation ahead of CEO Peter Molloy's address at the BIO CEO Conference in New York City.
- Posted by: Race Oncology
FeaturedMedia Release
Bisantrene Patent in US granted “Notice of Allowance”
A key Bisantrene patent has received “Notice of Allowance” in the United States, which extends the commercial exclusivity period for the drug in the American market. The patent
- Posted by: Race Oncology
Media Release
Race to present at J.P. Morgan Biotech Conference in US
Race Oncology is pleased to announce the company has been invited to present at the ‘Biotech Showcase’ during the J.P. Morgan Healthcare Conference in San Francisco next week.
- Posted by: Race Oncology